Inclusion complex of a new propiconazole derivative with β-cyclodextrin: NMR, ESI-MS and preliminary pharmacological studies

Results in Pharma Sciences

Volumn 1, Issue 1, 2011, Pages 27-37

  Marangoci, Narcisa ^a   Mares, Mihai ^b   Silion, Mihaela ^a   Fifere, Adrian ^a   Varganici, Cristian ^a,c   Nicolescu, Alina ^a   Deleanu, Calin ^a,d   Coroaba, Adina ^a   Pinteala, Mariana ^a   Simionescu, Bogdan C ^a,c  

^a PETRU PONI INSTITUTE OF MACROMOLECULAR CHEMISTRY   (Romania)

^b UNIVERSITY OF AGRICULTURAL SCIENCES AND VETERINARY MEDICINE   (Romania)

^c GHEORGHE ASACHI TECHNICAL UNIVERSITY OF IASI   (Romania)

^d INSTITUTE OF ORGANIC CHEMISTRY   (Romania)

Author keywords

Antifungal activity; Inclusion complex; Propiconazole; cyclodextrin

Indexed keywords

BETA CYCLODEXTRIN; DIMETHYL SULFOXIDE; HETEROCYCLIC COMPOUND; PROPICONAZOLE; PYRROLE DERIVATIVE;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANTIFUNGAL ACTIVITY; ARTICLE; BINDING AFFINITY; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; COLLISIONALLY ACTIVATED DISSOCIATION; COMPLEX FORMATION; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG SOLUBILITY; ELECTROSPRAY MASS SPECTROMETRY; ENCAPSULATION; FEMALE; HETERONUCLEAR MULTIPLE BOND CORRELATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; STOICHIOMETRY; THERMOGRAVIMETRY;

EID: 80052662829     PISSN: None     EISSN: 22112863     Source Type: Journal    
DOI: 10.1016/j.rinphs.2011.07.001     Document Type: Article

References (52)

1. Maertens JA. History of the development of azole derivatives. Clin Microbiol Infect 2004;10:1-10.
2. Richardson MD, Warnock DW. Fungal infection-diagnosis and management. London: Blackwell Publishing; 2003.
3. Bouza E, Munoz P. Epidemiology of candidemia in intensive care units. Int J Antimicrob Agents 2008;32:S87-91.
4. Beck-Sague CM, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. J Infect Dis 1993;167:1247-51.
5. Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. Clin Microbiol Rev 1999;12:40-79.
6. Vermes A, Guchelaar AJ, Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother 2000;46:171-9.
7. Ghannoum MA, Rice LB. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 1999;12:501-17.
8. Mellaerts R, Aerts A, Caremans TP, Vermant J, Van den Mooter G, Martens JA, et al. Growth of itraconazole nanofibers in supersaturated simulated intestinal fluid. Mol Pharm 2010;7:905-13.
9. Xu Y, Wang Y, Yan L, Liang RM, Dai BD, Tang RJ, et al. Proteomic analysis reveals a synergistic mechanism of fluconazole and berberine against fluconazole-resistant Candida albicans: endogenous ROS augmentation. J Proteome Res 2009;8:5296-304.
10. Kontoyiannis DP, Lewis RE. Antifungal drug resistance of pathogenic fungi. Lancet 2002;359:1135-44.
11. Roberts J, Schock K, Marino S, Andriole VT. Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis. Antimicrob Agents Chemother 2000;44:3381-8.
12. Guinea J, Bouza E. Isavuconazole: a new and promising antifungal triazole for the treatment of invasive fungal infections. Future Microbiol 2008;3:603-15.
13. Torres HA, Hachem RY, Chemaly FR, Kontoyiannis DP, Raad II. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis 2005;5:775-85.
14. Potts KT. The chemistry of 1,2,4-triazoles. Chem Rev 1961;61:87-127.
15. Szejtli J. Introduction and general overview of cyclodextrin chemistry. Chem Rev 1998;98:1743-53.
16. Davis ME, Brewster ME. Cyclodextrin-based pharmaceutics: past, present and future. Nat Rev Drug Discov 2004;3:1023-35.
17. Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins: basic science and product development.J Pharm Pharmacol 2010;62:1607-21.
18. Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins. Drug solubilization and stabilization.J Pharm Sci 1996;85:1017-25.
19. Spulber M, Pinteala M, Fifere A, Harabagiu V, Simionescu BC. Inclusion complexes of 5-flucytosine with β-cyclodextrin and hydroxypropyl-β-cyclodextrin: characterization in aqueous solution and in solid state. J Incl Phenom Macrocycl Chem 2008;62:117-25.
20. Spulber M, Pinteala M, Harabagiu V, Simionescu BC. Inclusion complexes of sulconazole with β-cyclodextrin and hydroxypropyl b-cyclodextrin: characterization in aqueous solution and in solid state. J Incl Phenom Macrocycl Chem 2008;61:41-51.
21. Spulber M, Pinteala M, Fifere A, Moldoveanu C, Mangalagiu I, Harabagiu V, Simionescu BC. Water soluble complexes of methyl β-cyclodextrin and sulconazole nitrate. J Incl Phenom Macrocycl Chem 2008;62:135-42.
22. Spulber M, Miron L, Mares M, Nastasa V, Pinteala M, Fifere A, et al. Water soluble 5 FC complexes, preliminary pharmacological studies. J Incl Phenom Macrocycl Chem 2009;65:431-5.
23. Miron L, Mares M, Nastasa V, Spulber M, Pinteala M, Fifere A, et al. Water soluble sulconazole-β-cyclodextrin complex: physico-chemical characterization and preliminary pharmacological studies. J Incl Phenom Macrocycl Chem2009;63:159-62.
24. Connors KA. Population characteristics of cyclodextrin complex stabilities in aqueous solution. J Pharm Sci 1995;84:843-8.
25. Connors KA. The stability of cyclodextrin complexes in solution. Chem Rev 1997;97:1325-57.
26. Ardeleanu R, Voiculescu N, Marcu M, Roman G, Buchidau C, Sacarescu L, et al. Synthesis of a new siloxane-crown ether polyamide. Macromol Rapid Commun 1997; 18:739-46.
27. Valica V. Studiu privind elaborarea unor produse farmaceutice antiinfec-tioase. Tehnologie, analiza si standardizare. PhD thesis. Republic of Moldavia: "N. Tetemitanu" State University, Chisinau; 2003.
28. Higuchi T, Connors KA. Phase-solubility techniques. Adv Anal Chem Instrum 1965;4:117-212.
29. Rodriguez-Tudela JL, Arendrup MC, Barchiesi F, Bille J, Chryssanthou E, Cuenca-Estrella M, et al. EUCAST definitive document E Def 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin Microbiol Infect 2008;14:398-405.
30. Dannaoui E, Lortholary O, Raoux D, Bougnoux ME, Galeazzi G, Lawrence C, et al. Comparative in vitro activities of caspofungin and micafungin, determined using the method of the European Committee on antimicrobial susceptibility testing, against yeast isolates obtained in France in 2005-2006. Antimicrob Agents Chemother 2008;52:778-81.
31. Dixon WJ, Mood AM. A method for obtaining analyzing sensitivity data. J Am Stat Assoc 1948;43:109-26.
32. Xue L, Fengqi Zhao F, Xing X, Zhou Z, Wang K, Gao H, et al. Dissolution properties of 1,2,4-triazole nitrate in N-Methyl pyrrolidone. J Chem Eng Data 2011;56:259-62.
33. Larina L, Lopyrev V. Nitroazoles: synthesis, structure and applications. New York: Springer; 2009.
34. Fatiha M, Khatmi DE, Largate L. Theoretical approach in the study of the inclusion processes of sulconazole with β-cyclodextrin. J Mol Liq 2010;154: 1-5.
35. Piel G, Dive G, Ervard B, Van Hees T, Henry de Hassonville S, Delattre L. Molecular modeling study of β- and g-cyclodextrin complexes with mico-nazole. Eur J Pharm Sci 2001;13:271-9.
36. Guo MQ, Zhang S, Song F, Wang D, Liu Z, Liu S. Studies on the non-covalent complexes between oleanolic acid and cyclodextrins using electro-spray ionization tandem mass spectrometry. J Mass Spectrom 2003;38: 723-31.
37. Guo MQ, Song F, Zhiqiang L, Shuying L. Characterization of non-covalent complexes of rutin with cyclodextrins by electrospray ionization tandem mass spectrometry. J Mass Spectrom 2004;39:594-9.
38. Kwon S, Lee W, Shin HJ, Yoon Sl, Kim YT, Kim YJ, et al. Characterization of cyclodextrin complexes of camostat mesylate by ESI mass spectrometry and NMR spectroscopy. J Mol Struct 2009;938:192-7.
39. Sagiraju S, Chen K, Cole RB, Branko S. Electrospray-ionization mass spectrometry study of cyclodextrin complexes with A007 prodrugs. Carbohydr Res 2009;344:2167-72.
40. de Paula WX, Denadai AML, Santoro MM, Braga ANG, Santos RAS, Sinisterra RD. Supramolecular interactions between losartan and hydroxypropyl-β-CD: ESI mass-spectrometry, NMR techniques, phase solubility, isothermal titration calorimetry and anti-hypertensive studies. Int J Pharm 2011;404: 116-23.
41. Benesi A, Hildebran JH. A spectrophotometric investigation of the interaction of iodine with aromatic. Hydrocarbons. J Am Chem Soc 1949;71: 2703-7.
42. Scott R. Some comments on the Benesi-Hildebrand equation. Rec Trav Chim 1956;75:787-9.
43. Loftsson T, Hreinsdottir D, Masson M. Evaluation of cyclodextrin solubilization of drugs. Int J Pharm 2005;302:18-28.
44. Chaudhuri RG, Paria S. Synthesis of sulfur nanoparticles in aqueous surfactant solutions. J Colloid Interface Sci 2010;343:439-46.
45. Li N, Chen SP, Gao SL. Cristal structure and thermal analysis of dia-quadi(1,2,4-triazol-5-one)Zinc(II) ion nitrate. J Therm Anal Calorim 2007;89: 583-8.
46. Vialaton D, Pilichowski JF, Baglio D, Paya-Perez A, Larsen B, Richard C. Phototransformation of propiconazole in aqueous media delphine. J Agric Food Chem 2001;49:5377-82.
47. Mitchell AG. Racemic drugs: racemic mixture, racemic compound, or pseu-doracemate? J Pharm Pharm Sci 1998;1:8-12.
48. Taneri F, Taner G, Aigner Z, Taneri MK. Improvement in the physicochemical properties of ketoconazole through complexation with cyclodextrin derivatives. J Incl Phenom Macrocycl Chem 2002;44:257-60.
49. Jiao H, Goh SH, Valiyaveettil S. Inclusion complexes of single-C60-end-capped poly(ethylene oxide) with cyclodextrins. Macromolecules 2002;35: 1399-402.
50. World Health Organization. The WHO recommended classification of pesticides by hazard and guidelines to classification 2009. Geneva (Switzerland): WHO Press; 2010.
51. Mares M, Nastasa V, Doroftei B, Moraru RF, Stefanache A. Comparative in vitro activities of fluconazole, voriconazole, and MXP-4509 against Romanian blood yeast isolates. Mycopathologia 2011, doi:10.1007/s1 1046-011-9455-1.
52. Pfizer Inc. Vfend (Voriconazole). Powder for oral suspension: material safety data sheet; version 1.2; 2007.